Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOCUS: CIK_D332 + Tafasitamab + Lenalidomide in R/R DLBCL
NCT07906080Phase 1Not yet recruiting
- Sponsor
- Istituto Oncologico Veneto
- Start
- Jan 2027
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CIK_D332 in diffuse large B-cell lymphoma (DLBCL), sponsored by Istituto Oncologico Veneto. Primary endpoints: Feasibility of CIK (CIK_D332) cell therapy at 3 years and Safety of CIK (CIK_D332) cell therapy at 3 years. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
CIK_D332
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07906080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07906080.